Myriad Awaits BRACAnalysis CDx Approval as it Works to Move Hereditary Cancer Testing to MyRisk | GenomeWeb

NEW YORK (GenomeWeb) — Fiscal year 2015 will see a significant shift for Myriad Genetics in hereditary cancer testing, as it aims to move all of its comprehensive BRACAnanlysis customers to its newer sequencing-based myRisk Hereditary Cancer panel by mid-2015.

Meanwhile, the company is hoping the US Food and Drug Administration will soon approve the companion diagnostic version of BRACAnalysis alongside AstraZeneca's olaparib

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.